D. Colorado· 7/11/2011
Wolfe v. Aspenbio Pharma, Inc.
Citations
- 275 F.R.D. 625
- 2011 U.S. Dist. LEXIS 75762
- 2011 WL 2726019
How courts have described this case
Verbatim parenthetical descriptions written by other courts when citing this decision. Ranked by citation-network relevance.
- finding typicality requirement satisfied where “both movant and members of the purported class allege that they purchased shares of AspenBio Pharma, Inc. (“AspenBio”
- “As for the requirement that the lead plaintiff otherwise satisfy the requirements of Rule 23, only two of the four requirements of Rule 23(a)—typicality and adequacy—impact the analysis of the lead plaintiff issue.”
Source: CourtListener parenthetical corpus (CC0).
Judges: Blackburn
Read full opinion on CourtListenerCites
4 cases in this archive are cited by this case.
- In Re Olsten Corp. Securities Litig.E.D. New York· 1998-05-04· cited 132×
- In re Ribozyme Pharmaceuticals, Inc. Securities LitigationD. Colorado· 2000-05-01· cited 24×
- Doll v. Chicago Title InsuranceD. Kansas· 2007-12-06· cited 19×
- In re Bausch & Lomb Inc. Securities LitigationW.D. New York· 2007-07-13· cited 6×
Sourced from CourtListener / Free Law Project (CC0).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.